MAPT and Alzheimer disease: Numerous studies have demonstrated its clinical value and accuracy in detecting pathological changes in AD by measuring plasma amyloid-β42:40 ratio and the levels of p-Tau 181 and p-Tau 217 in clinically defined patients (Mielke and Fowler, 2024).